StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Net Sales in Rest of World by Quarter

Net Sales in Rest of World ($M)

QuarterlyAnnual

Novartis Net Sales in Rest of World: $63M in Q3 2026, up 3.3% from a year earlier. That is the highest of the 16 quarters on record here.

Latest, Q3 2026
63
Period ended Sep 30, 2026
Change on a year earlier
+3.3%
61 in Q3 2025
History
16 quarters
Since Q3 2019
Sources
16
Documents cited below

Where the Q3 2026 figure comes from

“|| Lutathera | Oncology | GEP-NETs gastroenteropancreatic neuroendocrine tumors | 156 | 3 | 63 | 3 | 6 | 219 | 3 | 3”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in Rest of World ($M)Year on yearSource
Q3 2026Sep 30, 202663+3.3%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202662+8.8%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 202660+11.1%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202556+7.7%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202561+8.9%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 202557+11.8%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 202554+3.8%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 202452+18.2%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 202456+24.4%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 202451+15.9%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 202452+15.6%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 202344–Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 202345–Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 202344–Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 202345–Novartis Form 6-K (0001370368-23-000046) ↗
Q3 2019Sep 30, 201923–Novartis Form 6-K (0001370368-19-000062) ↗

Breakdown

What makes up net Sales in Rest of World

Cite this data

StockData. (2026). Novartis Net Sales in Rest of World ($M), quarterly Q3 2019–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-lutathera-row-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.